Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 61.25

-2.1%

3:21 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: atticus4paws who wrote (50708)	1/31/2019 12:50:04 PM
From: Miljenko Zuanic	Read Replies (3) of 52153

David Grainger is knowledgeable, maybe very knowledgeable, so it is worthy to do follow-up on his twits. Short chain FGF21 is viable molecules for metabolic condition (NASH, T2D, obesity,... and related), and BMY/other are after this moiety. BMY's PEG-FGF21 was studied in NASH and T2D. NASH data are of interest from this view: "We observed a significant decrease in absolute hepatic fat fraction in the group receiving 10 mg pegbelfermin daily (-6·8% vs -1·3%; p=0·0004) and in the group receiving 20 mg pegbelfermin weekly (-5·2% vs -1·3%; p=0·008) compared with the placebo group. " ncbi.nlm.nih.gov Daily SC dosing is not viable drug (hard to market, chronic, long term,...), while w-SC (if formulation improved and bump-up dose) may be very competitive and comparable to THRb agonist. I thought that BMY may go after MDGL (I bought MDGL with my own hype and hope for Acq.) , but IF they are comfortable with their own candidate....

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next